Decoding Lung Cancer Mutations: A 5-year Investigation in Ordu Province

Abstract

Aim: Lung cancer is the leading cause of cancer-related mortality worldwide and is most often diagnosed at an advanced stage. The increasing prominence of targeted therapy approaches in recent years has made the identification of genetic variations within tumors clinically significant. This study aimed to determine the prevalence of key mutations such as EGFR, ALK, KRAS, and PDL-1 in lung cancer cases over a five-year period, along with their distribution across histological subtypes and their association with demographic characteristics, specifically within the province of Ordu. Material and Method: This retrospective, cross-sectional study included a total of 202 patients who were diagnosed with Non-small cell lung cancer (NSCLC) and presented to the Medical Oncology Clinic of Ordu State Hospital between January 2019 and December 2023. Demographic data such as age and sex, histological subtypes, and genetic mutation analyses and other clinical parametres were evaluated. Mutation analysis focused on actionable biomarkers including EGFR, ALK, KRAS, and PDL-1, and their relationships with demographic characteristics were assessed. Results: The median age was 67 years (91.1% male). The most frequently observed histological subtype was squamous cell carcinoma (49.5%). In female patients, adenocarcinoma was the predominant (83.3%). The most commonly detected genetic alteration was PDL-1 (10.4%). EGFR mutations were significantly more frequent in older patients, whereas ALK mutations occurred in significantly younger patients. Conclusion: This study represents the first large-scale lung cancer mutation screening conducted specifically in the Ordu province. Our findings indicate regional differences, with PD-L1 being the most common alteration and squamous cell carcinoma the predominant subtype, in contrast to national data where EGFR mutations and adenocarcinoma are more frequent. These discrepancies indicate that regional characteristics and the genetic profile of the patient population should be taken into consideration during treatment planning.

Keywords

• Lung cancer
• Ordu province
• genetic analysis
• mutation

Kaynakça

1. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology, Non Small Cell Lung Cancer. 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf access date 01.07.2025.
2. Republic of Türkiye Ministry of Health GDoPH, Department of Cancer. Cancer Statistics of the Republic of Türkiye. https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri.html access date 27.06.2025.
3. World Health Organization IAfRC. Global Cancer Observatory. Lung. https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf access date 01.07.2025.
4. Ozcelik N, Aksel N, Bulbul Y, et al. Regional distribution of genetic mutation in lung cancer in Turkey (REDIGMA). Tuberk Toraks. 2019;67:197-204.
5. Soo RA, Reungwetwattana T, Perroud HA, et al. Prevalence of EGFR mutations in patients with resected stages I to III NSCLC: results from the EARLY-EGFR study. J Thorac Oncol. 2024;19:1449-59.
6. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892-911.
7. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361:958-67.
8. Ergün D, Savaş İ, Ergün R, et al. Lung cancer and family history of cancer. Tuberk Toraks. 2009;57:251-8.

9. Cangir AK, Yumuk PF, Sak SD, et al. Lung cancer in Turkey. J Thorac Oncol. 2022;17:1158-70.
10. Pauwels P. Mutations in lung cancer with clinical significance. Toraks Cerrahisi Bülteni. 2012;3:173-6.
11. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
12. Akyürek NÖB ND, Dizbay Sak S. Küçük Hücreli Dışı Akciğer Kanseri İçin Moleküler Testler Tanı Rehberi 2021. https://turkpath.org.tr/files/pdf/K%C3%BC%C3%A7%C3%BCk%20H%C3%BCcreli%20D%C4%B1%C5%9F%C4%B1%20Akci%C4%9Fer%20Kanseri%20%C4%B0%C3%A7in%20Molek%C3%BCler%20Testler%20Tan%C4%B1%20Rehberi%202021.pdf access date 01.07.2025.
13. Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985-93.
14. Barrera-Rodriguez R, Morales-Fuentes J. Lung cancer in women. Lung Cancer (Auckl). 2012;3:79-89.
15. Ceddia S, Landi L, Cappuzzo F. KRAS-mutant non-small-cell lung cancer: from past efforts to future challenges. Int J Mol Sci. 2022;23:9391.
16. Friedlaender A, Perol M, Banna GL, et al. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024;12:24.
17. Lim TKH, Skoulidis F, Kerr KM, et al. KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing. Lung Cancer. 2023;184:107293.
18. Cheng W, Kang K, Zhao A, et al. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54.
19. Yu H, Boyle TA, Zhou C, et al. PD-L1 expression in lung cancer. J Thorac Oncol. 2016;11:964-75. Erratum in: J Thorac Oncol. 2017;12:157-9.
20. Tfayli A, Rafei H, Mina A, et al. Prevalence of EGFR and ALK mutations in lung adenocarcinomas in the levant area - a prospective analysis. Asian Pac J Cancer Prev. 2017;18:107-14.